Смањење потребе за поновљеним тестирањем урина на лекове са сивом зоном одређеном мерном несигурношћу

Gray Zone for Urine Drug Testing

  • Kağan Huysal SBU BURSA YUKSEK IHTISAS RESEARCH AND EDUCATION HOSPITAL
  • Yasemin 1Department of Clinical Biochemistry, University of Health Sciences, Bursa Yüksek İhtisas Training And Research Hospital, Bursa, Turkey https://orcid.org/0000-0003-2415-0372
  • Hatice Azra Çağlak 1Department of Clinical Biochemistry, University of Health Sciences, Bursa Yüksek İhtisas Training And Research Hospital, Bursa, Turkey https://orcid.org/0000-0001-7970-5588
  • Meryem Rümeysa Yeşil 1Department of Clinical Biochemistry, University of Health Sciences, Bursa Yüksek İhtisas Training And Research Hospital, Bursa, Turkey https://orcid.org/0000-0002-6492-6094
DOI: https://doi.org/10.5937/jomb0-41777
Ključne reči: одрезати; сива зона; мерна несигурност; амфетамин; канабиноид; кокаин×

Sažetak



çeviri   tia.png                       Arama Modları               Arama Sonuçları Çeviri Sonucu İngilizce Sırpça                   Позадина На почетном тесту скрининга урина на недозвољене супстанце, ако је концентрација супстанце на или изнад утврђеног законског прага, пријављује се као позитивна. Поновљено тестирање са истим узорком ради верификације пре пријављивања је уобичајена пракса клиничких лабораторија. Ова студија је имала за циљ да утврди да ли се резултати мерне несигурности (МУ) могу користити за откривање сиве зоне како би се смањила поновљена тестирања. Материјали и методе Ретроспективна студија која користи податке из … ….. …… ……. лабораторијски информациони систем између 1.јануара 2020. и 1.јула 2022. године. Израчунате су МУ вредности за параметре амфетамина, канабиноида, кокаина и опиоида у урину коришћењем АДВИА Цхемистри реагенса (Сиеменс Хеалтхцаре Диагностиц Инц., Немачка) на Сиеменс АДВИА 1800 хемијском анализатору. Сива зона је дефинисана као гранична вредност ± МУ. Анализирани су узорци који су анализирани два пута у року од једног сата пре него што су пријављени за исти узорак урина. Резултати Од укупно 31.839 пацијената (16-65 година), поновљени су узорци урина, 319 амфетамина, 198 канабиноида, 112 кокаина и 125 тестова опијата. Просечна одступања између резултата поновљених тестова била су -7,64 (95% ЦИ: -13,71 до -1,57) за амфетамин и 1,16 (95% ЦИ: 0,31 до 2,01) за резултате канабиноида. Десет резултата теста на амфетамин, 12 канабиноида и 2 на кокаин промењено је са позитивних на негативне или негативне на позитивне на поновном тестирању, све у оквиру нивоа сиве зоне дефинисане МУ вредношћу. Закључци Неопходно је дефинисати сиву зону око граничне вредности за сваку недозвољену супстанцу на основу њеног МУ за поновно тестирање.

 

 

Reference

References


1. Li X, Moore S, Olson C. Urine drug tests: How to make the most of them. Current Psychiatry 2019;18(8):10-20.


2. Moeller KE, Kissack JC, Atayee RS, Lee KC. Clinical interpretation of urine drug tests: What clinicians need to know about urine drug screens. Mayo Clin Proc  2017;92(5):774-796. https://doi.org/10.1016/j.mayocp.2016.12.007


3. Kapur BM, Aleksa K. What the lab can and cannot do: clinical interpretation of drug testing results. Critical Rev in Clin Lab Scie 2020;57: 548-585. https://doi.org/10.1080/10408363.2020.1774493


4. Aslan R, Aydoğdu M, Akgür SA. Toxicological evaluation of alcohol and substance abuse in children and adolescents . J Ethn Subst Abuse. 2022;1-15. https://doi.org/10.1080/15332640.2022.2089424


5. Pereira P, Magnusson B, Theodorsson E, Westgard J, Encarnação P. Measurement uncertainty as a tool for evaluating the “grey-zone” to reduce the false negatives in immunochemical screening of blood donors for infectious diseases. Accred Qual Assur 2016; 21(1): 25-32. https://doi.org/10.1007/s00769-015-1180-x


6. Boyd J M,  Sadrzadeh SMH. Accurate results in the clinical laboratory. (Second Edition) Elsevier: (2019). Limitations of immunoassays for screening of drugs of abuse in urine.   233–242. https://doi.org/10.1016/B978-0-12-813776-5.00014-5


7. Pereira P. Eurachem/CITAC Guide “Assessment of performance and uncertainty in qualitative chemical analysis”—A medical laboratory perspective. Standards. 2022; 2(2):194-201. https://doi.org/10.3390/standards2020014


8. Kisner HJ. The gray zone. Clin Lab Manage Rev 1998;12(4):277-280.


9. International Organization for Standardization. ISO 15189 Medical laboratories-Requirements for quality and competence. 2012.


10. Ustundağ Y, Huysal K, Eren SE. Determining the need for repeat testing of blood ethanol concentration: Evaluation of the Synchron blood ethyl alcohol assay kit. J Med Biochem. 2019;38(3):317-322. doi: 10.2478/jomb-2018-0032


11. Marchei E, Ferri MA, Torrens M, Farre M, Pacifici R, Pichin S et al. Ultra-high performance liquid chromatography-high resolution mass spectrometry and high-sensitivity gas chromatography-Mass spectrometry screening of classic drugs and new psychoactive substances and metabolites in urine of consumers. Int J Mol Sci. 2021;22(8):4000. https://doi.org/10.3390/ijms22084000


12. Ustundağ Y, Huysal K. Measurement uncertainty of blood ethanol concentration in drink-driving cases in an emergency laboratory. Biochem Med (Zagreb). 2017;27(3):030708. https://hrcak.srce.hr/187591


13. Chua I, Petrides AK, Schiff GD, Ransohoff JR, Kantartjiss M, Streid J et al. Provider misinterpretation, documentation, and follow-up of definitive urine drug testing results. J Gen Intern Med 2020;35(1):283-290. https://doi.org/10.1007/s11606-019-05514-5


14.Jannetto PJ, Bratanow NC, Clark WA, Hamill-Ruth RJ, Hammett-Stabler CA, Huestis MA, et al. Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. J Appl Lab Med 2018;2(4):489-526. https://doi.org/10.1373/jalm.2017.023341


15. Pereira P, Magnusson B, Theodorsson E, Westgard J,Encarnação P.  Measurement uncertainty as a tool for evaluating the “grey-zone” to reduce the false negatives in immunochemical screening of blood donors for infectious diseases. Accred Qual Assur. 2016; 21(1): 25-32. https://doi.org/10.1007/s00769-015-1180-x


16. Lazzati JM, Zaidman V, Maceiras M, Belgorosky A, Chaler E. The use of a "gray zone" considering measurement uncertainty in pharmacological tests. The serum growth hormone stimulation test as an example. Clin Chem Lab Med 2016;54(11):e349-e351. https://doi.org/10.1515/cclm-2015-0954


17. Coste J, Pouchot J. A grey zone for quantitative diagnostic and screening tests. Int J Epidemiol. 2003;32(2):304-313. https://doi.org/10.1093/ije/dyg054


18. Pesce A, Rosenthal M, West R, West C, Crews B, Mikel C, et al. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician.2010; 13:273-281.


19. Snyder ML, Fantz CR, Melanson S. Immunoassay-based drug tests are inadequately sensitive for medication compliance monitoring in patients treated for chronic pain. Pain Physician 2017;20(2S):SE1-SE9.


20.Hashemi B, Eshghi Z, Ghabousian A, Safari S. Evaluation of intoxication in patients with acute impaired consciousness using rapid urine test tape; a diagnostic accuracy study. Front Emerg Med. 2022;6(4):e51.  https://doi.org/10.18502/fem.v6i4.10434


21. Sun SP, Garcia J, Hayden JA. Repeating critical hematology and coagulation values wastes resources, lengthens turnaround time, and delays clinical action. Am J Clin Pathol. 2018;149(3):247–52.  https://doi.org/10.1093/ajcp/aqx156


22. Soleimani N, Azadi A, Esmaeili MJ, Fatemeh Ghodsi, Reza Ghahramani, Azadeh Hafezi, et al. Termination of repeat testing in chemical laboratories based on practice guidelines: Examining the effect of rule-based repeat testing in a transplantation center. J Anal Methods Chem. 2021;2021:9955990. https://doi.org/10.1155/2021/9955990


 


 


 


 


 


 


 


 


 


 


 


 


 


 

Objavljeno
2023/04/06
Broj časopisa
Vol. 42 Br. 4 (2023): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2023 Kagan Huysal, Yasemin Üstündağ, Hatice Azra Çağlak, Meryem Rümeysa Yeşil

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.